本帖最后由 老马 于 2013-3-13 13:43 编辑 . v; i) ~# j! g0 R$ q$ w
) X; X( D5 F, H+ |, a2 _5 N
健择(吉西他滨)+顺铂+阿瓦斯汀% P% l& C* u$ o" S0 y7 F8 f
Gemzar +Cisplatin + Avastin
' A: S. e! G* ^/ _# khttp://annonc.oxfordjournals.org/content/21/9/1804.full
* Y% |! [4 F- {2 U8 }$ X! xOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) - O2 Z8 R9 y+ ?5 \
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
4 \4 B2 I6 u. e# R& | yResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
- k2 ]4 z2 M6 R+ R; g9 Z. P V
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 800)
* F5 K9 O! g, m" A% S/ o, W6 A7 G华为网盘附件:, c6 x; m$ W* O. [, @" A" i* P
【华为网盘】ava.JPG) z& K( s4 V; X' i( N
|